Inkodess Continuous

Drospirenone, the active ingredient in Inkodess Continuous, is a combined oral contraceptive presented as a tablet for oral use. Together with ethinylestradiol, it works to prevent pregnancy by suppressing the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, thickening cervical mucus and inducing endometrial changes in women of reproductive age through hormonal regulation during each menstrual cycle.

GNH USA supplies Inkodess Continuous as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across markets.

Inkodess Continuous, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

- Prevention of pregnancy: provides reliable contraceptive protection when taken as directed. - Menstrual cycle regulation: helps establish regular withdrawal bleeding and may reduce menstrual cramps. - Acne improvement: the anti‑androgenic component may lessen acne severity in some women.

Common Side Effects: - Nausea: mild stomach upset, especially when starting. - Breast tenderness: temporary swelling or discomfort. - Headache: mild to moderate intensity. - Irregular bleeding or spotting: changes in menstrual pattern.

Serious or Rare Side Effects: - Blood clots: deep vein thrombosis or pulmonary embolism. - Severe hypertension: sudden increase in blood pressure.

Before initiating Inkodess Continuous, consider the following precautions: - Assess thrombotic risk: evaluate personal or family history of clotting disorders. - Screen for hypertension: monitor blood pressure prior to use. - Avoid smoking: especially in women over 35 years of age. - Consider liver function: check for active hepatic disease. - Review medication list: assess for interacting drugs that may affect efficacy. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Inkodess Continuous may interact with other medicines as follows:

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampin antibiotics: can lower hormone levels, increasing risk of pregnancy. - Protease inhibitor antiretrovirals: may alter hormone metabolism and affect efficacy.

Moderate Interactions (Monitor Closely): - St. John’s wort: may decrease contraceptive effectiveness; monitor for breakthrough bleeding. - Azole antifungals (e.g., ketoconazole): may increase hormone concentrations, watch for side‑effects.